 earli phase II studi new deriv camptothecin treatment leukemia lymphoma earli phase II studi new camptothecin analog inhibitor topoisomeras patient refractori leukemia lymphoma differ treatment schedul multiinstitut cooper studi therapi complet remiss cr partial remiss pr assess non-hodgkin lymphoma nhl patient PR hodgkin diseas HD CR PR acut lymphoblast leukemia all PR acut myelogen leukemia aml patient singl infus week respons leukemia lymphoma patient sixty-minut infus day week day cr pr patient malign lymphoma sixty-minut infus day day week CR pr patient acut leukemia respons acut leukemia patient treatment schedul effect refractori leukemia lymphoma case relaps case relaps refractori case major side effect leukopenia gastrointestin GI effect refractori leukemia lymphoma clinic studi novel antitumor activ mode drug cross-resist avail antitumor drug